首页> 外文OA文献 >Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)

【2h】

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)

机译：从结肠直肠癌肝转移静脉转移静脉转移静脉化肝转移的药物发生决定因素（欧洲试验Optiliv，NCT00852228）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Francis Lévi; Abdoulaye Karaboué; Raphaël Saffroy; Christophe Desterke; Valerie Boige; Denis Smith; Mohamed Hebbar; Pasquale Innominato; Julien Taieb; Carlos Carvalho; Rosine Guimbaud; Christian Focan; Mohamed Bouchahda; René Adam; Michel Ducreux; Gérard Milano; Antoinette Lemoine;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228) [J] . FrancisLévi, AbdoulayeKaraboué, Rapha?lSaffroy, British Journal of Cancer . 2017,第7期

机译：三联肝动脉输注和西妥昔单抗静脉治疗结直肠癌肝转移的药物遗传学决定因素（欧洲试验OPTIILV，NCT00852228）
2. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV [J] . Levi F. A., Boige V., Hebbar M., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第2期

机译：多中心试验OPTILIV联合化学疗法和系统西妥昔单抗的肝动脉输注转化为大肠癌肝转移的切除术
3. Early tumour response as a survival predictor in previously-treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer [J] . Bouchahda Mohamed, Boige Valerie, Smith Denis, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：在接受三联肝动脉输注和西妥昔单抗静脉源性治疗的野生型KRAS结直肠癌肝转移患者中，先前接受治疗的患者的早期肿瘤反应可作为生存预测指标
4. Clinical Trial of Liposome-Adriamycin (Lipo-ADR) via the Portal Vein and Hepatic Artery for Prophylaxis and Treatment after Hepatic Resection on Liver Metastasis in Advanced Gastric Cancer [C] . I. Mizuno, T. Yotsuyanagi, M. Ishida, International Gastric Cancer Congress . 2009

机译：脂质体 - 亚霉素（Lipo-ADR）通过门静脉和肝动脉进行预防和治疗治疗晚期胃癌肝转移后的临床试验
5. Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV NCT00852228) [O] . Francis Lévi, Abdoulaye Karaboué, Raphaël Saffroy, 2017

机译：三联肝动脉输注和西妥昔单抗静脉治疗结直肠癌肝转移的药物遗传学决定因素（欧洲试验OPTILIVNCT00852228）
6. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer [O] . Bouchahda Mohamed, Boige Valérie, Smith Denis, 2016

机译：在接受三联肝动脉输注和西妥昔单抗静脉源性治疗的野生型KRAS结直肠癌肝转移患者中，先前接受治疗的患者的早期肿瘤反应可作为生存预测指标

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)

著录项

引文网络

相似文献

相关主题

期刊订阅